![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Lantheus
LNTH
Hutchmed (China)
HCM
Workday
WDAY
DexCom
DXCM
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
US Stock MarketDetailed Quotes
AUTL Autolus Therapeutics
- 1.820
- +0.030+1.68%
Close Feb 26 16:00 ET
- 1.820
- 0.0000.00%
Post 20:01 ET
484.34MMarket Cap-1.49P/E (TTM)
1.850High1.800Low1.15MVolume1.800Open1.790Pre Close2.09MTurnover0.84%Turnover RatioLossP/E (Static)266.12MShares6.62552wk High1.02P/B250.14MFloat Cap1.79052wk Low--Dividend TTM137.44MShs Float53.240Historical High--Div YieldTTM2.79%Amplitude1.600Historical Low1.820Avg Price1Lot Size
Autolus Therapeutics Stock Forum
Sign in to post a comment
$Autolus Therapeutics (AUTL.US)$ Autolus Therapeutics to Present Key Data on AUCATZYL At 2025 Tandem Meetings, Highlighting Cost Benefits and Clinical Outcomes! February 12 to 15, 2025
4
2
$Autolus Therapeutics (AUTL.US)$
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Autolus Therapeutics (NASDAQ: AUTL)presented clinical data updates at ASH 2024, featuring one oral and three poster presentations about obecabtagene autoleucel (obe-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
The FELIX trial demonstrated that obe-cel treatment achieved deep molecular remission in 84% of responde...
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Autolus Therapeutics (NASDAQ: AUTL)presented clinical data updates at ASH 2024, featuring one oral and three poster presentations about obecabtagene autoleucel (obe-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
The FELIX trial demonstrated that obe-cel treatment achieved deep molecular remission in 84% of responde...
1
$Autolus Therapeutics (AUTL.US)$ Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 6 to 8 PM pst 12/9/24!
4 MINUTES AGO, 7:30 PM EST
VIA GLOBENEWSWIRE
4 MINUTES AGO, 7:30 PM EST
VIA GLOBENEWSWIRE
1
$Autolus Therapeutics (AUTL.US)$ Nothing happened?
2
1
$Autolus Therapeutics (AUTL.US)$
ya I'm getting in here
ya I'm getting in here
1
2
$Autolus Therapeutics (AUTL.US)$
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
• AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy)
• Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL
• Conference call to be held on November 11 at 08:30 am EST/13:3...
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
• AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy)
• Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL
• Conference call to be held on November 11 at 08:30 am EST/13:3...
3
No comment yet
blessings u : Thank you for sharing.
Trytosaveabit OP blessings u : you’re welcome![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")